<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299843</url>
  </required_header>
  <id_info>
    <org_study_id>2014KYNO.51</org_study_id>
    <nct_id>NCT02299843</nct_id>
  </id_info>
  <brief_title>RALPPS Venus ALPPS for Hepatocellular Carcinoma</brief_title>
  <official_title>A Prospective Randomized Controlled Trial of Radio-frequency Assisted ALPPS（RALPPS）and Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy（ALPPS）in the Treatment of Hepatocellular Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently，the &quot;ALPPS&quot; (associating liver partition with portal vein ligation for staged
      hepatectomy) procedure which enables the rapid growth of the future liver remnant and extends
      surgical indication to patients with mid-advanced stage hepatocellular carcinoma becomes a
      research hot spot. However, the procedure has a high morbidity and mortality rate.Using
      radio-frequency ablation instead of in-situ split of liver to avoid forming a coagulation
      band in stage I will reduce the incidence of complications（bile leakage, abdominal
      infection,hemorrhage e.t.) The investigators named this technique as Radio-frequency Assisted
      Liver Partition with Portal vein ligation for staged hepatectomy （RALPPS）.Investigators
      hypothesized that the RALPPS might result in lower morbidity and mortality rate than ALPPS in
      the treatment of hepatocellular carcinoma . This Prospective Randomized Controlled Trial is
      on the Safety and Efficacy of radio-frequency assisted liver partition with portal vein
      ligation for staged hepatectomy for hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>morbidity during perioperation</measure>
    <time_frame>2 years</time_frame>
    <description>complications include bile leakage, abdominal infection, hemorrhage, PHLF e.t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality during perioperation</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>ALPPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using ALPPS for the the treatment of hepatocellular carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RALPPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I（RALPPS）.Habib 4X was used in RFA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RALPPS</intervention_name>
    <description>Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.</description>
    <arm_group_label>RALPPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ALPPS</intervention_name>
    <description>Treat the hepatocellular carcinoma with ALPPS.</description>
    <arm_group_label>ALPPS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An insufficient future liver remnant(FLR＜30% in normal hepatic function or FLR＜40%
             with hepatic cirrhosis or after chemotherapy）

          -  Liver function of Child-Pugh Class A or B.

          -  Liver Reserve Function：ICG-R15≤10％

          -  No evidence of coagulopathy: platelet count &gt; 50 × 109/L and a prolonged prothrombin
             time of &lt; 5 seconds.

        Exclusion Criteria:

          -  Patients met the inclusion criteria but declined to participate.

          -  Patients with severe portal hypertension, a history of esophageal variceal hemorrhage,
             severe hypersplenism syndrome, or refractory ascites.

          -  Main portal vein、inferior vena cava、common hepatic duct and hepatic vein have tumor
             thrombus.

          -  Extrahepatic or lymph node metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuansheng Ma, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Institute of hepatobiliary surgery,Southwest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Yan, Ph.D</last_name>
    <phone>+86-23-18502327600</phone>
    <email>yanjun@sina.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of hepatobiliary surgery,Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Yan, Ph.D</last_name>
      <phone>+86-23-18502327600</phone>
      <email>yanjun@sina.cn</email>
    </contact>
    <investigator>
      <last_name>Jun Yan, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Yan Jun</investigator_full_name>
    <investigator_title>institute of hepatobiliary surgery</investigator_title>
  </responsible_party>
  <keyword>RFA</keyword>
  <keyword>ALPPS</keyword>
  <keyword>hepatectomy</keyword>
  <keyword>morbidity and mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

